Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa in poor performance status advanced NSCLC
NCT00193336Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Mar 2003
- Primary completion
- Mar 2004
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by SCRI Development Innovations. Started Mar 2003; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00193336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193336.